Literature DB >> 21779873

Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program.

A R Majithia1, K A Jablonski, J B McAteer, K J Mather, R B Goldberg, S E Kahn, J C Florez.   

Abstract

AIMS/HYPOTHESIS: Individuals with impaired glucose tolerance have increased proinsulin levels, despite normal glucose or C-peptide levels. In the Diabetes Prevention Program (DPP), increased proinsulin levels predicted type 2 diabetes and proinsulin levels were significantly reduced following treatment with metformin, lifestyle modification or troglitazone compared with placebo. Genetic and physiological studies suggest a role for the zinc transporter gene SLC30A8 in diabetes risk, possibly through effects on insulin-processing in beta cells. We hypothesised that the risk allele at the type 2 diabetes-associated missense polymorphism rs13266634 (R325W) in SLC30A8 would predict proinsulin levels in individuals at risk of type 2 diabetes and may modulate response to preventive interventions.
METHODS: We genotyped rs13266634 in 3,007 DPP participants and examined its association with fasting proinsulin and fasting insulin at baseline and at 1 year post-intervention.
RESULTS: We found that increasing dosage of the C risk allele at SLC30A8 rs13266634 was significantly associated with higher proinsulin levels at baseline (p = 0.002) after adjustment for baseline insulin. This supports the hypothesis that risk alleles at SLC30A8 mark individuals with insulin-processing defects. At the 1 year analysis, proinsulin levels decreased significantly in all groups receiving active intervention and were no longer associated with SLC30A8 genotype (p = 0.86) after adjustment for insulin at baseline and 1 year. We found no genotype × treatment interactions at 1 year. CONCLUSIONS/
INTERPRETATION: In prediabetic individuals, genotype at SLC30A8 predicts baseline proinsulin levels independently of insulin levels, but does not predict proinsulin levels after amelioration of insulin sensitivity at 1 year.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21779873      PMCID: PMC3444290          DOI: 10.1007/s00125-011-2234-1

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  A genome-wide association study identifies novel risk loci for type 2 diabetes.

Authors:  Robert Sladek; Ghislain Rocheleau; Johan Rung; Christian Dina; Lishuang Shen; David Serre; Philippe Boutin; Daniel Vincent; Alexandre Belisle; Samy Hadjadj; Beverley Balkau; Barbara Heude; Guillaume Charpentier; Thomas J Hudson; Alexandre Montpetit; Alexey V Pshezhetsky; Marc Prentki; Barry I Posner; David J Balding; David Meyre; Constantin Polychronakos; Philippe Froguel
Journal:  Nature       Date:  2007-02-11       Impact factor: 49.962

2.  Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Authors:  Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon
Journal:  Diabetes       Date:  2005-08       Impact factor: 9.461

3.  Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study.

Authors:  Anthony J G Hanley; Ralph D'Agostino; Lynne E Wagenknecht; Mohammed F Saad; Peter J Savage; Richard Bergman; Steven M Haffner
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

4.  Fasting proinsulin concentrations predict the development of type 2 diabetes.

Authors:  N J Wareham; C D Byrne; R Williams; N E Day; C N Hales
Journal:  Diabetes Care       Date:  1999-02       Impact factor: 19.112

5.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

6.  Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion.

Authors:  N Wijesekara; F F Dai; A B Hardy; P R Giglou; A Bhattacharjee; V Koshkin; F Chimienti; H Y Gaisano; G A Rutter; M B Wheeler
Journal:  Diabetologia       Date:  2010-04-28       Impact factor: 10.122

7.  Three-dimensional structure of beta-cell-specific zinc transporter, ZnT-8, predicted from the type 2 diabetes-associated gene variant SLC30A8 R325W.

Authors:  Rob Nm Weijers
Journal:  Diabetol Metab Syndr       Date:  2010-06-05       Impact factor: 3.320

8.  The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients--the EUGENE2 study.

Authors:  T W Boesgaard; J Zilinskaite; M Vänttinen; M Laakso; P-A Jansson; A Hammarstedt; U Smith; N Stefan; A Fritsche; H Häring; M Hribal; G Sesti; D P Zobel; O Pedersen; T Hansen
Journal:  Diabetologia       Date:  2008-03-07       Impact factor: 10.122

9.  Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men.

Authors:  Alena Stancáková; Teemu Kuulasmaa; Jussi Paananen; Anne U Jackson; Lori L Bonnycastle; Francis S Collins; Michael Boehnke; Johanna Kuusisto; Markku Laakso
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

10.  Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program.

Authors:  Allan F Moore; Kathleen A Jablonski; Jarred B McAteer; Richa Saxena; Toni I Pollin; Paul W Franks; Robert L Hanson; Alan R Shuldiner; William C Knowler; David Altshuler; Jose C Florez
Journal:  Diabetes       Date:  2008-06-10       Impact factor: 9.461

  10 in total
  13 in total

1.  Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish.

Authors:  Nisa M Maruthur; Jeanne M Clark; Mao Fu; W H Linda Kao; Alan R Shuldiner
Journal:  Diabetologia       Date:  2014-10-28       Impact factor: 10.122

Review 2.  Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

Authors:  David Della-Morte; Raffaele Palmirotta; Ashish K Rehni; Donatella Pastore; Barbara Capuani; Francesca Pacifici; Maria Laura De Marchis; Kunjan R Dave; Alfonso Bellia; Giuseppe Fogliame; Patrizia Ferroni; Giulia Donadel; Francesco Cacciatore; Pasquale Abete; Chuanhui Dong; Antonello Pileggi; Mario Roselli; Camillo Ricordi; Paolo Sbraccia; Fiorella Guadagni; Tatjana Rundek; Davide Lauro
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

Review 3.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

Review 4.  Loss of Znt8 function in diabetes mellitus: risk or benefit?

Authors:  Carla P Barragán-Álvarez; Eduardo Padilla-Camberos; Nestor F Díaz; Agustín Cota-Coronado; Claudia Hernández-Jiménez; Carlos C Bravo-Reyna; Nestor E Díaz-Martínez
Journal:  Mol Cell Biochem       Date:  2021-03-05       Impact factor: 3.396

5.  The influence of rare genetic variation in SLC30A8 on diabetes incidence and β-cell function.

Authors:  Liana K Billings; Kathleen A Jablonski; Rachel J Ackerman; Andrew Taylor; Rebecca R Fanelli; Jarred B McAteer; Candace Guiducci; Linda M Delahanty; Dana Dabelea; Steven E Kahn; Paul W Franks; Robert L Hanson; Nisa M Maruthur; Alan R Shuldiner; Elizabeth J Mayer-Davis; William C Knowler; Jose C Florez
Journal:  J Clin Endocrinol Metab       Date:  2014-01-28       Impact factor: 5.958

6.  Type 2 Diabetes Mellitus and the Association of Candidate Genes in Asian Indian Population from Hyderabad, India.

Authors:  Imran Ali Khan; Subhadra Poornima; Parveen Jahan; Pragna Rao; Qurratulain Hasan
Journal:  J Clin Diagn Res       Date:  2015-11-01

7.  The new perspectives on genetic studies of type 2 diabetes and thyroid diseases.

Authors:  Min Xu; Yufang Bi; Bin Cui; Jie Hong; Weiqing Wang; Guang Ning
Journal:  Curr Genomics       Date:  2013-03       Impact factor: 2.236

8.  Zinc-rs13266634 and the arrival of diabetes pharmacogenetics: the "zinc mystique".

Authors:  Nisa M Maruthur; Braxton D Mitchell
Journal:  Diabetes       Date:  2014-05       Impact factor: 9.461

9.  Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Authors:  Jose C Florez; Kathleen A Jablonski; Jarred B McAteer; Paul W Franks; Clinton C Mason; Kieren Mather; Edward Horton; Ronald Goldberg; Dana Dabelea; Steven E Kahn; Richard F Arakaki; Alan R Shuldiner; William C Knowler
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

10.  Zinc and Other Metals Deficiencies and Risk of Type 1 Diabetes: An Ecological Study in the High Risk Sardinia Island.

Authors:  Paolo Valera; Patrizia Zavattari; Alessandro Sanna; Salvatore Pretti; Alberto Marcello; Carla Mannu; Clara Targhetta; Graziella Bruno; Marco Songini
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.